Ilaria Roato

TL;DR: Evidence is provided for the utility of CEP-18770 as a novel orally active proteasomesome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.

TL;DR: It is demonstrated that IL-7 supports OC formation by inducing the TNF-α production and low RANKL levels, which synergize in promoting osteoclastogenesis, and shows the capability ofIL-7 to stimulate spontaneous osteOClastogenesis of bone metastatic patients and to induce osteoclineogenesis in cancer patients without bone involvement.

TL;DR: It is shown that RANK is expressed by solid tumors, with high concordance between bone metastasis and corresponding primary tumor, which highlights the central role of RANK/RANKL/OPG pathway as potential therapeutic target not only inBone metastasis management, but also in the adjuvant setting.

TL;DR: It is found that cancer patients with bone involvement display an increase in osteoclasts precursors, compared with both healthy controls and cancer patients without bone metastases, which suggests that TNF‐α may be responsible for osteoclastogenesis in these tumors.

TL;DR: The experience of this lab to exploit human multiple myeloma (MM), a neoplastic expansion of plasma cells, as a model to investigate tumor viability and enzymatic functions in conditions mimicking what happens in vivo is reported.